Register
|
Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC
Specialties >>
AML
Bladder Cancer
Breast Cancer
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
GI Cancers
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Liquid Biopsies
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Thyroid Cancers
More >>
Partners >>
Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
Evolving Paradigms
2019
|
2018
|
2017
|
2016
|
2015
Ovarian Suppression in Breast Cancer
Chronic Lymphocytic Leukemia
Cutaneous Squamous Cell Carcinoma
Role of Immunotherapy in NSCLC
Mantle Cell Lymphoma
Breast Cancer: Focus on CDK4&6 Inhibitors
Immunotherapy in Nonsquamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Soft Tissue Sarcoma
Clinical Advances in Prostate Cancer
Triple Negative Breast Cancer
BRAF-Mutant Melanoma
CDK4&6 Inhibition
Pancreatic Cancer
Sequencing Strategies in Prostate Cancer
Bladder Cancer
Lymphoma
Immuno-Oncology: Checkpoint Inhibitors
Squamous NSCLC
Gynecologic Cancer
JTT Articles
Participating Practices Commend CMS for OCM Changes
The Role of Liquid Biopsy in NSCLC Continues to Emerge
Rare Incidence of ICI-Related Hepatotoxicity Frequently Ends in Treatment Discontinuation
>> View Peer-Reviewed Articles
Most Popular
Bevacizumab/Erlotinib Combination Provides Another Frontline Option in EGFR+ NSCLC
Case 1: Immunotherapy in Locally Advanced NSCLC
TMB Shows Promise as Biomarker for Durvalumab Activity in NSCLC
Investigating Osimertinib for Brain Activity in EGFR-Mutated Lung Cancer
